Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 22, 2023, titled "Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study".
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 22, 2023, titled "Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study".